Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Prostate Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 84 articles: HTML format Text format

Single Articles

March 2010
1. KOUMAKPAYI IH , Le Page C, Mes-Masson AM, Saad DF, et al
   Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.
   Br J Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
2. ESCAFF S , Fernandez JM, Gonzalez LO, Suarez A, et al
   Study of matrix metalloproteinases and their inhibitors in prostate cancer.
   Br J Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
3. REID AH , Attard G, Ambroisine L, Fisher G, et al
   Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
   Br J Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. BARWICK BG , Abramovitz M, Kodani M, Moreno CS, et al
   Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
   Br J Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. KILPELAINEN TP , Tammela TL, Maattanen L, Kujala P, et al
   False-positive screening results in the Finnish prostate cancer screening trial.
   Br J Cancer. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
6. AHMED HU , Emberton M
   Reply to S Eggener, M Gonzalgo and O Yossepowitch: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'
   Br J Cancer. 2009;101:2059.
   PubMed     Text format     Related articles   
   
   
   
7. EGGENER S , Gonzalgo M, Yossepowitch O
   Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'.
   Br J Cancer. 2009;101:2057-8.
   PubMed     Text format     Related articles   
   
   
   
8. AHMED HU , Emberton M
   Reply to TS Clark: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'
   Br J Cancer. 2009;101:2056.
   PubMed     Text format     Related articles   
   
   
   
9. CLARK TS
   Regarding: 'high-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'.
   Br J Cancer. 2009;101:2055.
   PubMed     Text format     Related articles   
   
   
   
10. YUEN HF , Chiu YT, Chan KK, Chan YP, et al
    Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. BROWN MD , Hart C, Gazi E, Gardner P, et al
    Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. KOTE-JARAI Z , Leongamornlert D, Tymrakiewicz M, Field H, et al
    Mutation analysis of the MSMB gene in familial prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2009
13. RAY AM , Zuhlke KA, Johnson GR, Levin AM, et al
    Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. EVANS S , Metcalfe C, Patel B, Ibrahim F, et al
    Clinical presentation and initial management of Black men and White men with prostate cancer in the United Kingdom: the PROCESS cohort study.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. GRANDOCH M , Rose A, Ter Braak M, Jendrossek V, et al
    Epac inhibits migration and proliferation of human prostate carcinoma cells.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. HEIJNSDIJK EA , der Kinderen A, Wever EM, Draisma G, et al
    Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. FAIRLEY L , Baker M, Whiteway J, Cross W, et al
    Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. TRAISH AM , Morgentaler A
    Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. DARBY S , Murphy T, Thomas H, Robson CN, et al
    Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
20. ORSINI N , Bellocco R, Bottai M, Pagano M, et al
    A prospective study of lifetime physical activity and prostate cancer incidence and mortality.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. TERAKAWA T , Miyake H, Furukawa J, Ettinger SL, et al
    Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. SEATON A , Maxwell PJ, Hill A, Gallagher R, et al
    Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. ULMER H , Borena W, Rapp K, Klenk J, et al
    Serum triglyceride concentrations and cancer risk in a large cohort study in Austria.
    Br J Cancer. 2009;101:1202-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
24. MELLADO B , Font A, Alcaraz A, Aparicio LA, et al
    Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. SIERON P , Hader C, Hatina J, Engers R, et al
    DKC1 overexpression associated with prostate cancer progression.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. BRATT O , Haggman M, Ahlgren G, Nordle O, et al
    Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. OLEA-HERRERO N , Vara D, Malagarie-Cazenave S, Diaz-Laviada I, et al
    Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
    Br J Cancer. 2009;101:940-50.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. BERMEJO JL , Sundquist J, Hemminki K
    Bladder cancer in cancer patients: population-based estimates from a large Swedish study.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
29. FOSTER CS , Dodson AR, Ambroisine L, Fisher G, et al
    Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. TERRY S , Ploussard G, Allory Y, Nicolaiew N, et al
    Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. ZHANG H , Bermejo JL, Sundquist J, Hemminki K, et al
    Prostate cancer as a first and second cancer: effect of family history.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. MURTOLA TJ , Tammela TL, Maattanen L, Ala-Opas M, et al
    Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
33. KORECKIJ T , Nguyen H, Brown LG, Yu EY, et al
    Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
    Br J Cancer. 2009;101:263-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. METCALFE C , Tilling K, Davis M, Lane JA, et al
    Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
35. AHN J , Moore SC, Albanes D, Huang WY, et al
    Height and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. ISMAIL M , Bokaee S, Davies J, Harrington KJ, et al
    Inhibition of the aquaporin 3 water channel increases the sensitivity of prostate cancer cells to cryotherapy.
    Br J Cancer. 2009;100:1889-95.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. PARK SY , Wilkens LR, Franke AA, Le Marchand L, et al
    Urinary phytoestrogen excretion and prostate cancer risk: a nested case-control study in the Multiethnic Cohort.
    Br J Cancer. 2009;16.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. ALLAN L , Baker L, Dewar J, Eljamel S, et al
    Suspected malignant cord compression - improving time to diagnosis via a 'hotline': a prospective audit.
    Br J Cancer. 2009;100:1867-72.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. AHMED HU , Zacharakis E, Dudderidge T, Armitage JN, et al
    High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. FERRUCCI LM , Cross AJ, Graubard BI, Brinton LA, et al
    Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
41. TRAVIS RC , Spencer EA, Allen NE, Appleby PN, et al
    Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. WALLSTROM P , Bjartell A, Gullberg B, Olsson H, et al
    A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. MCINTOSH HM , Neal RD, Rose P, Watson E, et al
    Follow-up care for men with prostate cancer and the role of primary care: a systematic review of international guidelines.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. BALANATHAN P , Williams ED, Wang H, Pedersen JS, et al
    Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. EKLUND CM , Tammela TL, Schleutker J, Hurme M, et al
    C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. GRONWALD J , Cybulski C, Piesiak W, Suchy J, et al
    Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband.
    Br J Cancer. 2009;100:1508-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
47. BARBORO P , Repaci E, Rubagotti A, Salvi S, et al
    Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. NILSSON J , Skog J, Nordstrand A, Baranov V, et al
    Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. TRAUGER R , Corey E, Bell D, White S, et al
    Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).
    Br J Cancer. 2009;100:1068-72.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
50. BERNEY DM , Gopalan A, Kudahetti S, Fisher G, et al
    Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.
    Br J Cancer. 2009;100:888-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. PASHAYAN N , Duffy SW, Pharoah P, Greenberg D, et al
    Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. KAWANO Y , Diez S, Uysal-Onganer P, Darrington RS, et al
    Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
53. ESCHWEGE P , Moutereau S, Droupy S, Douard R, et al
    Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study.
    Br J Cancer. 2009;100:608-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
54. DIAZ R , Nguewa PA, Diaz-Gonzalez JA, Hamel E, et al
    The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
55. ANG JE , Olmos D, de Bono JS
    CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. MCPHERSON RA , Galettis PT, de Souza PL
    Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. ALONZI R , Padhani AR, Maxwell RJ, Taylor NJ, et al
    Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
58. TRETLI S , Hernes E, Berg JP, Hestvik UE, et al
    Association between serum 25(OH)D and death from prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. KOTE-JARAI Z , Jugurnauth S, Mulholland S, Leongamornlert DA, et al
    A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
    Br J Cancer. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
60. ANDREN O , Garmo H, Mucci L, Andersson SO, et al
    Incidence and mortality of incidental prostate cancer: a Swedish register-based study.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
61. GRUNFELD E , Watters JM, Urquhart R, O'Rourke K, et al
    A prospective study of peri-diagnostic and surgical wait times for patients with presumptive colorectal, lung, or prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
62. VAN WEERDEN WM , Bangma C, de Wit R
    Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
63. WILSON C , Scullin P, Worthington J, Seaton A, et al
    Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
64. YAP WN , Chang PN, Han HY, Lee DT, et al
    gamma-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
65. COOPER CS , Foster CS
    Concepts of epigenetics in prostate cancer development.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. KNIGHT JF , Shepherd CJ, Rizzo S, Brewer D, et al
    TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. FAIRLEY L , Forman D, West R, Manda S, et al
    Spatial variation in prostate cancer survival in the Northern and Yorkshire region of England using Bayesian relative survival smoothing.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. BAKER MJ , Gazi E, Brown MD, Shanks JH, et al
    FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
69. TAGG SL , Foster PA, Leese MP, Potter BV, et al
    2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
70. MCCALL P , Witton CJ, Grimsley S, Nielsen KV, et al
    Is PTEN loss associated with clinical outcome measures in human prostate cancer?
    Br J Cancer. 2008;99:1296-301.
    PubMed     Text format     Related articles    Abstract available
    
    
    
71. SUN ZJ , Wang Y, Cai Z, Chen PP, et al
    Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
72. DIALLO JS , Betton B, Parent N, Peant B, et al
    Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
73. TIRELLI U
    Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.
    Br J Cancer. 2008;99:1364.
    PubMed     Text format     Related articles   
    
    
    
74. MATHEW P , Thall PF, Wen S, Bucana C, et al
    Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
75. JESSER C , Mucci L, Farmer D, Moon C, et al
    Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
76. CLARKE NW
    Survival from prostate cancer in England and Wales up to 2001.
    Br J Cancer. 2008;99 Suppl 1:S78-9.
    PubMed     Text format     Related articles   
    
    
    
77. ROWAN S , Rachet B, Alexe DM, Cooper N, et al
    Survival from prostate cancer in England and Wales up to 2001.
    Br J Cancer. 2008;99 Suppl 1:S75-7.
    PubMed     Text format     Related articles   
    
    
    
78. KRISTIANSEN G , Fritzsche FR, Wassermann K, Jager C, et al
    GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
    Br J Cancer. 2008;99:939-48.
    PubMed     Text format     Related articles    Abstract available
    
    
    
79. NAROD SA , Seth A, Nam R
    Fusion in the ETS gene family and prostate cancer.
    Br J Cancer. 2008;99:847-51.
    PubMed     Text format     Related articles    Abstract available
    
    
    
80. METCALFE C , Evans S, Ibrahim F, Patel B, et al
    Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
81. LAMMERS T , Subr V, Peschke P, Kuhnlein R, et al
    Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy.
    Br J Cancer. 2008;99:900-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
82. LAMBERT LA , Whyteside AR, Turner AJ, Usmani BA, et al
    Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
83. NTOUROUPI TG , Ashraf SQ, McGregor SB, Turney BW, et al
    Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope.
    Br J Cancer. 2008;99:789-95.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
84. LANDERS KA , Samaratunga H, Teng L, Buck M, et al
    Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer.
    Br J Cancer. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: